Literature DB >> 30355097

Progression From Paroxysmal to Sustained Atrial Fibrillation Is Associated With Increased Adverse Events.

Hisashi Ogawa1, Yoshimori An1, Syuhei Ikeda1, Yuya Aono1, Kosuke Doi1, Mitsuru Ishii1, Moritake Iguchi1, Nobutoyo Masunaga1, Masahiro Esato2, Hikari Tsuji3, Hiromichi Wada4, Koji Hasegawa4, Mitsuru Abe1, Gregory Y H Lip5,6, Masaharu Akao1.   

Abstract

Background and Purpose- Atrial fibrillation (AF) is a common arrhythmic disorder among the elderly and sometimes progresses from paroxysmal to sustained (persistent or permanent) types. Clinical outcomes of patients with progression of AF were unknown. This study assessed the characteristics of patients with AF progression and the impact of AF progression on various clinical events. Methods- The Fushimi AF Registry is a community-based prospective survey of the patients with AF in Fushimi-ku, Kyoto. Analyses were performed on 4045 patients, which included 1974 paroxysmal AF (PAF; 48.8%) and 2071 sustained (persistent or permanent) AF (SAF; 51.2%) at baseline. Results- During the median follow-up period of 1105 days, progression of AF occurred in 252 patients with PAF (4.22 per 100 person-years). Multivariate Cox regression analysis demonstrated that progression of AF was significantly associated with an increased risk of ischemic stroke or systemic embolism (adjusted hazard ratio [HR], 4.10; 95% CI, 1.95-8.24; P<0.001 [versus PAF without progression]; adjusted HR, 2.20; 95% CI, 1.11-4.00; P=0.025 [versus SAF]) during progression period from paroxysmal to sustained forms. The risk after the progression was equivalent to SAF (adjusted HR, 1.54; 95% CI, 0.78-2.75; P=0.201 [versus SAF]). AF progression was significantly associated with a higher risk of hospitalization for heart failure (adjusted HR, 2.70; 95% CI, 1.55-4.52; P<0.001 [versus PAF without progression]; adjusted HR, 1.81; 95% CI, 1.08-2.88; P=0.026 [versus SAF]). Conclusions- Progression of AF was associated with increased risk of clinical adverse events during arrhythmia progression period from PAF to SAF among Japanese patients with AF. The risk of adverse events was transiently elevated during progression period from PAF to SAF and declined to the level equivalent to SAF after the progression. Clinical Trial Registration- URL: http://www.umin.ac.jp/ctr/ . Unique identifier: UMIN000005834.

Entities:  

Keywords:  aged; atrial fibrillation; heart failure; humans; thromboembolism

Mesh:

Year:  2018        PMID: 30355097     DOI: 10.1161/STROKEAHA.118.021396

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  12 in total

1.  Atrial fibrillation pattern and factors affecting the progression to permanent atrial fibrillation.

Authors:  Vincenzo Livio Malavasi; Elisa Fantecchi; Virginia Tordoni; Laura Melara; Andrea Barbieri; Marco Vitolo; Gregory Y H Lip; Giuseppe Boriani
Journal:  Intern Emerg Med       Date:  2020-11-07       Impact factor: 3.397

2.  Predicting cerebral infarction in patients with atrial fibrillation using machine learning: The Fushimi AF registry.

Authors:  Hidehisa Nishi; Naoya Oishi; Hisashi Ogawa; Kishida Natsue; Kento Doi; Osamu Kawakami; Tomokazu Aoki; Shunichi Fukuda; Masaharu Akao; Tetsuya Tsukahara
Journal:  J Cereb Blood Flow Metab       Date:  2021-12-01       Impact factor: 6.960

3.  Age-dependent risk for thromboembolism in atrial fibrillation: The Fushimi AF registry.

Authors:  Masahiro Esato; Yoshimori An; Hisashi Ogawa; Hiromichi Wada; Koji Hasegawa; Hikari Tsuji; Mitsuru Abe; Masaharu Akao
Journal:  Int J Cardiol Heart Vasc       Date:  2022-05-19

4.  The impact of atrial fibrillation type on the risks of thromboembolic recurrence, mortality and major haemorrhage in patients with previous stroke: A systematic review and meta-analysis of observational studies.

Authors:  Antonia Mentel; Terence J Quinn; Alan C Cameron; Kennedy R Lees; Azmil H Abdul-Rahim
Journal:  Eur Stroke J       Date:  2020-01-13

5.  Association of Exercise-Based Cardiac Rehabilitation with Progression of Paroxysmal to Sustained Atrial Fibrillation.

Authors:  Benjamin J R Buckley; Stephanie L Harrison; Elnara Fazio-Eynullayeva; Paula Underhill; Deirdre A Lane; Dick H J Thijssen; Gregory Y H Lip
Journal:  J Clin Med       Date:  2021-01-23       Impact factor: 4.241

6.  Plasma Galectin-3 is associated with progression from paroxysmal to persistent atrial fibrillation.

Authors:  Qianhui Wang; Li Xu; Ying Dong; Yuan Fu; Yuxia Pan; Qianran Luan; Ye Liu; Zheng Liu; Xinchun Yang; Mulei Chen; Yuanfeng Gao
Journal:  BMC Cardiovasc Disord       Date:  2021-05-02       Impact factor: 2.174

7.  Detecting paroxysmal atrial fibrillation from normal sinus rhythm in equine athletes using Symmetric Projection Attractor Reconstruction and machine learning.

Authors:  Ying H Huang; Jane V Lyle; Anisa Shahira Ab Razak; Manasi Nandi; Celia M Marr; Christopher L-H Huang; Philip J Aston; Kamalan Jeevaratnam
Journal:  Cardiovasc Digit Health J       Date:  2022-02-14

8.  Premature Beats Rejection Strategy on Paroxysmal Atrial Fibrillation Detection.

Authors:  Xiangyu Zhang; Jianqing Li; Zhipeng Cai; Lina Zhao; Chengyu Liu
Journal:  Front Physiol       Date:  2022-04-01       Impact factor: 4.755

Review 9.  Current Therapeutic Approach to Atrial Fibrillation in Patients with Congenital Hemophilia.

Authors:  Minerva Codruta Badescu; Oana Viola Badulescu; Lacramioara Ionela Butnariu; Mariana Floria; Manuela Ciocoiu; Irina-Iuliana Costache; Diana Popescu; Ioana Bratoiu; Oana Nicoleta Buliga-Finis; Ciprian Rezus
Journal:  J Pers Med       Date:  2022-03-23

10.  One-year clinical outcomes of anticoagulation therapy among Japanese patients with atrial fibrillation: The Hyogo AF Network (HAF-NET) Registry.

Authors:  Kiyohiro Hyogo; Akihiro Yoshida; Motoshi Takeuchi; Kunihiko Kiuchi; Koji Fukuzawa; Mitsuru Takami; Atsushi Kobori; Katsunori Okajima; Michio Odake; Toshio Okada; Akira Shimane; Yasuhiro Kawahara; Junichi Sekiya; Hiroshi Sano; Yasunori Ichikawa; Ken-Ichi Hirata
Journal:  J Arrhythm       Date:  2019-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.